

**Amendments to the Claims:**

The following Listing of Claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

We claim:

1. (Currently amended) A transdermal drug delivery device for delivering a pharmaceutically active agent comprising:

- a) a reservoir comprising a ~~releasably stored dosage of the~~ therapeutically effective amount of a pharmaceutically active agent; and
- b) a substantially continuous, translucent inorganic barrier layer adjacent to at least a portion of the reservoir.

2. (Original) A transdermal drug delivery device for delivering a pharmaceutically active agent according to claim 1, further comprising a backing film substrate.

3. (Original) A transdermal drug delivery device for delivering a pharmaceutically active agent according to claim 2, wherein the backing film substrate is translucent.

4. (Original) A transdermal drug delivery device for delivering a pharmaceutically active agent according to claim 2, wherein the inorganic barrier layer directly adjoins the backing film substrate.

5. (Withdrawn) ~~A transdermal drug delivery device for delivering a pharmaceutically active agent according to claim 1, further comprising a layer comprising a polymer adjoining the inorganic barrier layer.~~

6. (Withdrawn) ~~A transdermal drug delivery device for delivering a pharmaceutically active agent according to claim 5, wherein the polymer is crosslinked.~~

7. (Withdrawn) ~~A transdermal drug delivery device for delivering a pharmaceutically active agent according to claim 5, comprising a plurality of inorganic barrier layers.~~

8. (Withdrawn) ~~A transdermal drug delivery device for delivering a pharmaceutically active agent according to claim 5, comprising a plurality of layers comprising a polymer.~~

9. (Withdrawn) ~~A transdermal drug delivery device for delivering a pharmaceutically active agent according to claim 5, wherein the polymer is a polyacrylate or polymethacrylate.~~

10. (Original) A transdermal drug delivery device for delivering a pharmaceutically active agent according to claim 1, wherein the inorganic barrier layer directly adjoins the reservoir.

11. (Currently amended) A transdermal drug delivery device for delivering a pharmaceutically active agent according to claim 1, wherein the inorganic barrier layer is greater than 10 nm and less than about 200 nm thick.

12. (Original) A transdermal drug delivery device for delivering a pharmaceutically active agent according to claim 1, wherein the inorganic barrier layer comprises a material selected from the group consisting of indium tin oxide, aluminum oxide, silicon oxide, aluminum-silicon-oxide, aluminum-silicon-nitride, and aluminum-silicon-oxy-nitride.

13. (Original) A transdermal drug delivery device for delivering a pharmaceutically active agent according to claim 1, comprising a plurality of inorganic barrier layers.

14. (Original) A transdermal drug delivery device for delivering a pharmaceutically active agent according to claim 1, wherein the reservoir comprises a pressure-sensitive adhesive.

15. (Withdrawn) ~~A transdermal drug delivery device for delivering a pharmaceutically active agent comprising:~~

~~—— a) a reservoir comprising a releasably stored dosage of the pharmaceutically active agent;~~

~~— b) a flexible, translucent polymeric film backing; and  
c) a translucent barrier adjacent to the polymeric film backing;  
wherein the device is characterized in that the moisture vapor transmission rate across the  
backing and barrier is less than about 2 g/m<sup>2</sup>/day and the oxygen transmission rate across the  
backing and barrier is less than about 10 cm<sup>3</sup>/m<sup>2</sup>/day.~~

~~16. (Withdrawn) A transdermal drug delivery device for delivering a pharmaceutically active agent according to claim 15, wherein the barrier comprises an inorganic barrier layer.~~

~~17. (Withdrawn) A method of drug delivery to a mammal comprising:~~

- ~~a) providing a reservoir comprising a pharmaceutically active agent;~~
- ~~b) providing a substantially continuous, translucent inorganic barrier layer adjacent to at least a portion of one surface of the reservoir;~~
- ~~c) placing the surface of the reservoir opposed to the surface adjacent to the inorganic barrier layer in a delivering relationship to the skin surface of the mammal; and~~
- ~~d) allowing the reservoir to remain in a delivering relationship to the skin for a period of time sufficient to provide a therapeutic effect.~~

~~18. (Withdrawn) A method of drug delivery according to claim 17, wherein the reservoir directly adjoins the skin.~~

~~19. (Withdrawn) A method of drug delivery to a mammal comprising:~~

- ~~a) providing a transdermal drug delivery device according to claim 15;~~
- ~~b) placing the device in a delivering relationship to the skin surface of the mammal; and~~
- ~~c) allowing the device to remain in a delivering relationship to the skin for a period of time sufficient to provide a therapeutic effect.~~

~~20. (Withdrawn) A method of drug delivery according to claim 19, wherein the reservoir directly adjoins the skin.~~